Complete Filing Data
American Exceptionalism Acquisition Corp. A reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $515.9 thousand for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean American Exceptionalism Acquisition Corp. A did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 |
|---|---|
| Other Nonoperating Income Expense | $37.7K |
| Other Nonoperating Income | $37.7K |
| Operating Income Loss | -$10.5M |
| Net Income Loss | -$10.4M |
| General And Administrative Expense | $111.2K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 |
|---|---|
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $515.9K |
| Temporary Equity Aggregate Amount Of Redemption Requirement | $348.4M |
| Stockholders Equity | -$19.9M |
| Retained Earnings Accumulated Deficit | -$19.9M |
| Preferred Stock Value | $0.00 |
| Payment Of Related Party Debt | |
| Other Receivables Net Current | $8.3K |
| Offering Costs Included In Accrued Offering Costs | |
| Liabilities Current | $101.2K |
| Liabilities And Stockholders Equity | $349.2M |
| Liabilities | $20.8M |
| Deferred Underwriting Fee Payable Non Current | $10.4M |
| Deferred Underwriting Fee Payable | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | |
| Assets Held In Trust Noncurrent | $348.4M |
| Assets Current | $736.3K |
| Assets | $349.2M |
| Advisory Fee Payable Non Current | $10.4M |
| Accrued Offering Costs | $85.0K |
| Accrued Liabilities Current | $16.2K |
| Notes Payable Current |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 |
|---|---|
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $882.4K |
| Temporary Equity Aggregate Amount Of Redemption Requirement | $345.0M |
| Stockholders Equity | -$19.8M |
| Retained Earnings Accumulated Deficit | -$19.8M |
| Preferred Stock Value | $0.00 |
| Payment Of Related Party Debt | $8.3K |
| Other Receivables Net Current | $8.3K |
| Offering Costs Included In Accrued Offering Costs | $125.2K |
| Liabilities Current | $295.2K |
| Liabilities And Stockholders Equity | $346.2M |
| Liabilities | $21.0M |
| Deferred Underwriting Fee Payable Non Current | $10.4M |
| Deferred Underwriting Fee Payable | $10.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $882.4K |
| Assets Held In Trust Noncurrent | $345.0M |
| Assets Current | $1.0M |
| Assets | $346.2M |
| Advisory Fee Payable Non Current | $10.4M |
| Accrued Offering Costs | $125.2K |
| Accrued Liabilities Current | $47.2K |
| Notes Payable Current | $122.8K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 |
|---|---|
| Proceeds From Issuance Of Private Placement | $1.8M |
| Proceeds From Notes Payable | |
| Proceeds From Issuance Of Common Stock | |
| Payments To Acquire Restricted Investments | |
| Payments Of Stock Issuance Costs | |
| Net Cash Provided By Used In Operating Activities | |
| Net Cash Provided By Used In Investing Activities | |
| Net Cash Provided By Used In Financing Activities | |
| Increase Decrease In Prepaid Expense | |
| Increase Decrease In Long Term Prepaid Insurance | |
| Increase Decrease In Advisory Fee Payable | |
| Increase Decrease In Accounts Payable And Accrued Liabilities |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 |
|---|---|
| Proceeds From Issuance Of Private Placement | $1.8M |
| Proceeds From Notes Payable | $100.0K |
| Proceeds From Issuance Of Common Stock | $344.8M |
| Payments To Acquire Restricted Investments | $345.0M |
| Payments Of Stock Issuance Costs | $388.6K |
| Net Cash Provided By Used In Operating Activities | -$320.6K |
| Net Cash Provided By Used In Investing Activities | -$345.0M |
| Net Cash Provided By Used In Financing Activities | $346.2M |
| Increase Decrease In Prepaid Expense | $151.7K |
| Increase Decrease In Long Term Prepaid Insurance | $136.2K |
| Increase Decrease In Advisory Fee Payable | $10.4M |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $47.2K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 |
|---|---|
| Stock Issued During Period Value New Issues | |
| Stock Issued1 | |
| Sale Of Stock Consideration Received On Transaction | |
| Prepaid Expense Noncurrent | $146.1K |
| Prepaid Expense Current | $212.1K |
| Other Noncash Expense | |
| Noninterest Expense Investment Advisory Fees | |
| Formation Cost In Exchange Of Issuance Of Ordinary Shares | |
| Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs | |
| Adjustments To Additional Paid In Capital Accretion To Redemption Amount | |
| Additional Paid In Capital | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 |
|---|---|
| Stock Issued During Period Value New Issues | $25.0K |
| Stock Issued1 | $16.5K |
| Sale Of Stock Consideration Received On Transaction | $1.8M |
| Prepaid Expense Noncurrent | $136.2K |
| Prepaid Expense Current | $151.7K |
| Other Noncash Expense | $22.8K |
| Noninterest Expense Investment Advisory Fees | $10.4M |
| Formation Cost In Exchange Of Issuance Of Ordinary Shares | 8.5K |
| Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs | -$2.7K |
| Adjustments To Additional Paid In Capital Accretion To Redemption Amount | $11.2M |
| Additional Paid In Capital | $0.00 |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.